HK1112021A1 - Variant forms of urate oxidase and use thereof - Google Patents

Variant forms of urate oxidase and use thereof

Info

Publication number
HK1112021A1
HK1112021A1 HK08106827.8A HK08106827A HK1112021A1 HK 1112021 A1 HK1112021 A1 HK 1112021A1 HK 08106827 A HK08106827 A HK 08106827A HK 1112021 A1 HK1112021 A1 HK 1112021A1
Authority
HK
Hong Kong
Prior art keywords
variant forms
urate oxidase
urate
oxidase
variant
Prior art date
Application number
HK08106827.8A
Other languages
English (en)
Chinese (zh)
Inventor
Jacob Hartman
Simona Mendelovitz
Original Assignee
Crealta Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crealta Pharmaceuticals Llc filed Critical Crealta Pharmaceuticals Llc
Publication of HK1112021A1 publication Critical patent/HK1112021A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK08106827.8A 2005-04-11 2008-06-19 Variant forms of urate oxidase and use thereof HK1112021A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67057305P 2005-04-11 2005-04-11
PCT/US2006/013660 WO2006110819A2 (en) 2005-04-11 2006-04-11 Variant forms of urate oxidase and use thereof

Publications (1)

Publication Number Publication Date
HK1112021A1 true HK1112021A1 (en) 2008-08-22

Family

ID=37075495

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106827.8A HK1112021A1 (en) 2005-04-11 2008-06-19 Variant forms of urate oxidase and use thereof

Country Status (27)

Country Link
US (12) US8188224B2 (hu)
EP (3) EP3321359B1 (hu)
JP (6) JP2008535500A (hu)
KR (1) KR20080009111A (hu)
CN (1) CN101198693B (hu)
AU (1) AU2006235495B2 (hu)
BR (1) BRPI0612941A2 (hu)
CA (1) CA2604399A1 (hu)
CY (1) CY1124138T1 (hu)
CZ (1) CZ2007695A3 (hu)
DK (1) DK3321359T3 (hu)
ES (2) ES2856881T3 (hu)
FR (1) FR15C0067I2 (hu)
HK (1) HK1112021A1 (hu)
HU (2) HUE052976T2 (hu)
IL (1) IL186510A (hu)
LT (1) LT3321359T (hu)
MX (1) MX2007012547A (hu)
NZ (1) NZ562292A (hu)
PL (2) PL215285B1 (hu)
PT (1) PT3321359T (hu)
RU (4) RU2451074C2 (hu)
SG (1) SG161247A1 (hu)
SI (1) SI3321359T1 (hu)
TW (1) TWI366467B (hu)
WO (1) WO2006110819A2 (hu)
ZA (1) ZA200708650B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2361190T3 (es) 1998-08-06 2011-06-14 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
CZ2007695A3 (cs) 2005-04-11 2008-02-27 Savient Pharmaceuticals, Inc. Variantní formy urátoxidázy a jejich použití
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
HU230758B1 (hu) * 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102051348B (zh) 2009-10-27 2012-10-03 重庆富进生物医药有限公司 人源化重组尿酸酶及其突变体
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CN102634492B (zh) * 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN102260653B (zh) * 2011-06-30 2013-04-03 荣俊 一种peg化重组猪-人尿酸氧化酶融合蛋白的制备及应用方法
CN103834623B (zh) * 2014-02-11 2017-11-07 中国药科大学 具有催化活性的人源尿酸氧化酶
BR112017024212A2 (pt) 2015-05-15 2018-07-17 Medimmune Llc sequências de uricases melhoradas e métodos de tratamento
EP3538135A4 (en) * 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
AU2020276510B2 (en) * 2019-05-10 2024-08-01 Hangzhou Grand Biologic Pharmaceutical Inc. Polyethylene glycol-modified urate oxidase
WO2021042055A1 (en) * 2019-08-30 2021-03-04 Horizon Pharma Rheumatology Llc Pegloticase for treatment of gout in renal transplant recipients
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN112980808A (zh) * 2019-12-12 2021-06-18 深圳迈瑞生物医疗电子股份有限公司 尿酸酶、及其制备方法和用途
CN113144174B (zh) * 2020-01-22 2023-07-04 杭州远大生物制药有限公司 治疗高尿酸相关性疾病的药物
US20240002814A1 (en) 2020-11-03 2024-01-04 Protalix Ltd. Modified uricase and uses thereof
CN114438047A (zh) * 2020-11-05 2022-05-06 重庆派金生物科技有限公司 制备聚乙二醇修饰的尿酸氧化酶的方法
WO2022214086A1 (zh) * 2021-04-09 2022-10-13 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
CN117230034A (zh) * 2023-10-16 2023-12-15 临沂大学 一种高稳定性哺乳动物尿酸氧化酶突变体

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279489C (hu)
DE279486C (hu)
US1141973A (en) 1911-05-22 1915-06-08 Jesse W Nichols Can-cap with vent-shield.
DE837379C (de) 1950-04-20 1955-08-16 Nordwind G M B H Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4027676A (en) 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (ja) 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE2943016C2 (de) 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DE3005897A1 (de) 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
US4315852A (en) 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
FR2497006A1 (fr) 1980-12-24 1982-06-25 Ind Electro Ste Gle Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
USD279486S (en) 1983-04-25 1985-07-02 International Jensen Incorporated Controller for a video game or the like
US4719179A (en) 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja) 1985-06-05 1994-09-14 サッポロビール株式会社 ウリカ−ゼおよびその製造法
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
JPS63203548A (ja) 1987-02-12 1988-08-23 四国化工機株式会社 飲料用密封容器の製造装置
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1286591C (en) 1987-12-18 1991-07-23 Douglas B. Taylor Apparatus for opening and closing roll-up door
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja) 1988-02-24 1989-08-30 Hoechst Japan Kk 末熟児頭蓋内出血阻止剤
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
JP3148208B2 (ja) 1988-10-31 2001-03-19 富士ゼロックス株式会社 マルチ出力トレイ付プリントサーバおよびプリントシステム
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
JPH0354581A (ja) 1989-07-24 1991-03-08 Nec Corp 電子写真系プリンタの現像カートリッジ
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
WO1991002977A1 (en) 1989-08-23 1991-03-07 Hadassah Medical Organization Wound healing preparations containing heparanase
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
JPH03148208A (ja) 1989-11-02 1991-06-25 Mikimoto Seiyaku Kk 皮膚外用剤
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH06255079A (ja) 1993-03-08 1994-09-13 Akira Totsuka 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法
IL109259A0 (en) 1993-04-09 1994-07-31 Bio Technology General Corp Novel polypeptide having factor Xa inhibitory activity
US5863534A (en) 1993-04-09 1999-01-26 Bio-Technology General Corp. Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
AU6586394A (en) 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5795776A (en) * 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (fi) 1994-05-31 1996-06-10 Exavena Oy Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996017929A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CN1168495C (zh) 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US5816397A (en) 1997-01-21 1998-10-06 Ogio International, Inc. Golf club carrying apparatus
WO1998035026A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
KR100369838B1 (ko) 1997-02-26 2003-09-29 주식회사 엘지생명과학 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (ja) * 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
PT1084136E (pt) 1998-06-01 2004-12-31 Genentech Inc Separacao de monomeros de anticorpos dos seus multimeros atraves da utilizacao de cromatografia de troca ionica
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU770014B2 (en) 1998-08-06 2004-02-12 Duke University Peg-urate oxidase conjugates and use thereof
ES2361190T3 (es) 1998-08-06 2011-06-14 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
EP2277998B1 (en) * 1998-08-06 2016-04-20 Duke University Urate oxidase
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
KR19980069019U (ko) 1998-09-29 1998-12-05 양영석 신축성 핸드폰 케이스
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6429860B1 (en) 1999-06-15 2002-08-06 Visicomp, Inc. Method and system for run-time visualization of the function and operation of a computer program
US20020068857A1 (en) 2000-02-14 2002-06-06 Iliff Edwin C. Automated diagnostic system and method including reuse of diagnostic objects
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20050084478A1 (en) 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
JP2004536786A (ja) 2001-03-02 2004-12-09 メディミューン，インコーポレイテッド インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20040105839A1 (en) 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
ZA200504990B (en) 2003-01-09 2006-08-30 Genentech Inc Purification of polypeptides
JP4273998B2 (ja) 2004-02-26 2009-06-03 学校法人東海大学 プロテオーム解析用試料の調製方法
US20050282877A1 (en) 2004-04-13 2005-12-22 Becker Bryan N Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers
WO2006017206A2 (en) 2004-07-12 2006-02-16 Tengen Biomedical Company Flavivirus vaccine
GB0420888D0 (en) 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006110761A2 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
CZ2007695A3 (cs) 2005-04-11 2008-02-27 Savient Pharmaceuticals, Inc. Variantní formy urátoxidázy a jejich použití
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US20100163021A1 (en) 2006-02-22 2010-07-01 Novartis Pharma Ag System for delivering nebulized cyclosporine and methods of treatment
HU230758B1 (hu) 2006-04-12 2018-03-28 Crealta Pharmaceuticals LLC 100% Fehérjék tisztítása kationos felületaktív anyaggal
NL1031926C2 (nl) 2006-05-31 2007-12-03 X Flow Bv Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum.
EP2100122A4 (en) 2006-11-21 2010-01-06 Univ Southern California POLY (ETHYLENE GLYCOL) ASSAYS FOR DETECTION OF ANTIBODIES AND KITS FOR CARRYING OUT SAID ASSAYS
EP3320895B1 (en) 2007-10-10 2021-03-10 Kyowa Hakko Bio Co., Ltd. Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine
CN101168052A (zh) 2007-10-26 2008-04-30 西安交通大学 一种防治高尿酸血症及痛风的肠溶制剂
US8748496B2 (en) 2008-09-15 2014-06-10 Elan Pharmaceuticals, Inc. Methods of treatment of hyperuricemia and associated disease states
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP5451464B2 (ja) 2010-03-09 2014-03-26 キヤノン株式会社 帯電装置
US9402827B2 (en) 2010-03-30 2016-08-02 Ardea Biosciences, Inc. Treatment of gout
AU2011380510B2 (en) 2011-11-04 2016-05-12 Cymabay Therapeutics, Inc. Methods for treating gout flares
JP5746101B2 (ja) 2012-06-18 2015-07-08 コスメディ製薬株式会社 マイクロニードルの迅速溶解法
GB2512876A (en) 2013-04-09 2014-10-15 Image Analysis Ltd Methods and apparatus for quantifying inflammation
CU24406B1 (es) 2014-04-04 2019-05-03 Pfizer 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida
KR20180120753A (ko) 2016-03-11 2018-11-06 셀렉타 바이오사이언시즈, 인크. Peg화 우리카제의 제제 및 용량
US20180008665A1 (en) 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20220409620A1 (en) 2016-11-11 2022-12-29 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
KR20190124295A (ko) 2017-03-11 2019-11-04 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
WO2020160324A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2021042055A1 (en) 2019-08-30 2021-03-04 Horizon Pharma Rheumatology Llc Pegloticase for treatment of gout in renal transplant recipients
BR112023002458A2 (pt) 2020-08-10 2023-05-02 Horizon Therapeutics Usa Inc Métodos de tratamento da gota

Also Published As

Publication number Publication date
HU229068B1 (hu) 2013-07-29
RU2012106148A (ru) 2013-08-27
SG161247A1 (en) 2010-05-27
AU2006235495A1 (en) 2006-10-19
US20170298326A1 (en) 2017-10-19
FR15C0067I1 (hu) 2015-11-13
US20230034252A1 (en) 2023-02-02
ES2538357T3 (es) 2015-06-19
US8188224B2 (en) 2012-05-29
US10160958B2 (en) 2018-12-25
IL186510A0 (en) 2008-01-20
PL3321359T3 (pl) 2021-06-28
ZA200708650B (en) 2009-07-29
JP2013135676A (ja) 2013-07-11
CA2604399A1 (en) 2006-10-19
RU2007141625A (ru) 2009-05-20
RU2451074C2 (ru) 2012-05-20
JP2016171819A (ja) 2016-09-29
HUP0700730A3 (en) 2012-09-28
HUE052976T2 (hu) 2021-06-28
DK3321359T3 (da) 2021-03-08
CN101198693B (zh) 2013-03-27
FR15C0067I2 (fr) 2016-02-12
RU2610680C9 (ru) 2018-05-30
BRPI0612941A2 (pt) 2012-10-02
JP2019070006A (ja) 2019-05-09
PT3321359T (pt) 2021-03-11
AU2006235495B2 (en) 2012-04-12
US20170313995A1 (en) 2017-11-02
JP2018015005A (ja) 2018-02-01
EP1871874A2 (en) 2008-01-02
SI3321359T1 (sl) 2021-07-30
US9926537B2 (en) 2018-03-27
US8541205B2 (en) 2013-09-24
US9670467B2 (en) 2017-06-06
ES2856881T3 (es) 2021-09-28
WO2006110819A3 (en) 2007-03-08
US10731139B2 (en) 2020-08-04
JP2015107122A (ja) 2015-06-11
WO2006110819A2 (en) 2006-10-19
US11345899B2 (en) 2022-05-31
US20190316097A1 (en) 2019-10-17
NZ562292A (en) 2009-11-27
US20170313994A1 (en) 2017-11-02
RU2012106150A (ru) 2013-08-27
MX2007012547A (es) 2008-03-11
EP2947145A1 (en) 2015-11-25
US20170313993A1 (en) 2017-11-02
TWI366467B (en) 2012-06-21
EP3321359B1 (en) 2020-12-02
US9017980B2 (en) 2015-04-28
KR20080009111A (ko) 2008-01-24
IL186510A (en) 2013-03-24
HUP0700730A2 (en) 2008-03-28
US20150197732A1 (en) 2015-07-16
US20090169534A1 (en) 2009-07-02
CN101198693A (zh) 2008-06-11
RU2012106116A (ru) 2013-08-27
CZ2007695A3 (cs) 2008-02-27
US20130330803A1 (en) 2013-12-12
US20120309085A1 (en) 2012-12-06
US9926538B2 (en) 2018-03-27
TW200640482A (en) 2006-12-01
JP2008535500A (ja) 2008-09-04
US11781119B2 (en) 2023-10-10
US20170321193A1 (en) 2017-11-09
EP3321359A1 (en) 2018-05-16
PL387691A1 (pl) 2009-09-14
PL215285B1 (pl) 2013-11-29
LT3321359T (lt) 2021-05-10
CY1124138T1 (el) 2022-05-27
US20210079362A1 (en) 2021-03-18
EP1871874B1 (en) 2015-04-08
RU2610680C2 (ru) 2017-02-14

Similar Documents

Publication Publication Date Title
IL281228A (en) Variant configuration of urate oxidase and its uses
TWI366467B (en) Variant forms of urate oxidase and use thereof
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
AP2358A (en) Thiazole compounds and methods of use.
IL188078A0 (en) Nano-ionic liquids and methods of use
EP1945137A4 (en) PARTLY COVERED STENT DEVICES AND APPLICATION METHODS
IL182202A0 (en) Cupredoxin derived transport agents and methods of use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
EP1945819A4 (en) GENE EXPRESSION PROFILES AND METHOD OF USE
PT2380573E (pt) Acetato de eslicarbazepina e métodos de utilização
EP1946007A4 (en) ANDROSTERONE DERIVATIVES AND METHODS OF USE
IL181819A0 (en) Enzyme inhibitors and uses thereof
IL177647A0 (en) Use of enzyme
GB0520930D0 (en) Composition and method of use
EP1965829A4 (en) ALTERNATIVE OXIDASE AND ITS USES
EP1978999A4 (en) ISOLATED MCPIP PROTEIN AND METHODS OF USE
IL192438A0 (en) Stable enzymatic preparations and methods of use thereof
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use
ZA200709864B (en) Eslicarbazepine acetate and methods of use
AU2005907121A0 (en) Micro-identifiers and methods of application thereof
GB0517168D0 (en) Composition and method of use
GB0416832D0 (en) Enzyme and processes